Set & Setting
The concept of 'set and setting' is critical in psychedelic research, influencing therapeutic outcomes in clinical environments. Creating optimal conditions is essential for maximising the efficacy and safety of psychedelic-assisted therapies, particularly in the context of mental health disorders.
What is Set & Setting?
Set and setting refer to the psychological (set) and environmental (setting) contexts in which a psychedelic experience occurs, impacting the individual's responses to the compounds used.
The psychological state includes mood, mindset, and expectations, while the environment encompasses the physical and social surroundings during the psychedelic experience.
Poorly managed set and setting can lead to adverse experiences, making it crucial in clinical settings to ensure a supportive and nurturing environment for patients.
Current Treatments
Standard-of-care treatments for mood disorders, including Major Depressive Disorder (MDD), often involve pharmacotherapy, psychotherapy, or a combination of both. Common medications include SSRIs and cognitive-behavioural therapy (CBT). Recent advances also explore psychedelic-assisted therapies.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Set & Setting.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Numerous trials confirm its efficacy in treating mood disorders, with strong emphasis on set and setting. | Large | High | Consistent |
| MDMA Demonstrated robust therapeutic effects in PTSD, underpinned by supportive set and setting. | Large | High | Consistent |
| LSD Emerging studies indicate potential benefits offset by varied experiences based on set and setting. | Medium | Moderate | Inconsistent |
| Ayahuasca Research suggests therapeutic potential, significantly influenced by cultural and personal contexts. | Medium | Moderate | Inconsistent |
| Ketamine Clinically applied for depression, effectiveness is greatly enhanced in supportive environments. | Large | Moderate | Consistent |
Psilocybin and Set & Setting
Psilocybin, a naturally occurring psychedelic compound, has shown significant promise in treating Major Depressive Disorder and other mental health conditions. Its effects are highly influenced by the set and setting; a supportive environment enhances positive therapeutic outcomes, while a poor context can lead to challenging experiences or cognitive distress. Ongoing trials are emphasising the need for well-structured therapeutic settings.
MDMA and Set & Setting
MDMA, known for its empathogenic effects, has been utilised in therapy primarily for PTSD. The efficacy of MDMA-assisted therapy is profoundly strengthened in controlled settings, where the therapeutic alliance and environmental factors contribute positively to the experience. Research highlights how the quality of set and setting significantly reduces adverse psychological effects during sessions.
LSD and Set & Setting
LSD has been studied for its potential in various mental health applications, including anxiety and depression. Its effects can vary widely based on the individual’s mental state and the setting in which it is administered. When provided in a carefully curated therapeutic environment, LSD can facilitate profound insights and emotional breakthroughs.
Key Insights
- 1
Psychedelics can significantly alter emotional processing and cognition, with set and setting playing a vital role in shaping these experiences.
- 2
Clinical trials have shown that psilocybin-assisted therapy can reduce depressive symptoms when conducted in a supportive environment.
- 3
Different musical genres and therapeutic guidance during psychedelic sessions can influence emotional responses and overall therapeutic outcomes.
- 4
Research indicates that both recreational and therapeutic uses of psychedelics are heavily modulated by set and setting, impacting both efficacy and safety.
- 5
Studies suggest that a well-structured therapeutic framework for administering psychedelics can help mitigate the risks of challenging experiences.
Industrial Landscape
Key industry players such as MAPS, Multidisciplinary Association for Psychedelic Studies, and various academic institutions are heavily involved in research. Non-profits and advocacy groups are also working to promote policy changes and access to psychedelic-assisted therapies.
Quick Indicators
\"Ongoing clinical evaluations are investigating Set & Setting as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Set & Setting.